-
-
Administers Grant
-
(Takeda cTTP-2) A Phase 3b, open-label, continuation study of prophylactic and on-demand treatment of cTTP with
TAK-755 (rADAMTS-13, also known as BAX 930/SHP655)
-
12091912 INR Project
-
2019 ASH RTAF
-
2020 ASH RTAF
-
4202-HEM-201 Pro00109172
-
A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects W/ Essential Thromboythemia Who Are Resistant to or Intolerant of
-
A Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Subjects with Sickle Cell Disease
-
A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects with Congenital Fibrinogen Deficiency with a Prospective Followup Component
-
A Phase 2, Uncontrolled, Two-stage, Dose-escalations Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical activity of OMS721 in Adults with Thrombotic Microangiopathies
-
A Phase 2a, Randomised, Double Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-B thalassemia.
-
A Phase I/II Open-Label Safety and Dose-Finding Study of Adeno- Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B
-
A Phase II trial of topical sodium nitrite in patients with sickle cell disease and leg ulcers Cost Reimbursable
-
A Whole Blood Collection from subjects clinicially diagnosed with PNH
-
A randomized Phase 2 study evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of rozanolixizumab relative to placebo in participants with primary antiphospholipid syndrome.
-
AG348-C-011 extension study of adult subjects with Pyruvate Kinase Deficiency
-
AGIOS AG348-C-017 A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating
the Efficacy and Safety of Mitapivat in Subjects With Non-Transfusion-Dependent
Alpha- or Beta-Thalassemia (ENERGIZE)
-
AGIOS AG348-C-018 A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating
the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent
Alpha- or Beta-Thalassemia (ENERGIZE-T)
-
AKIRA Bio study
-
ALEXION Study ITP Translational Study
-
ALXN1007-APS-201 An Open-label proof of concept Phase IIa trial of ALXN1007 for the treatment of non-criteria manifestations of Antiphospholipid Syndrome
-
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF RIVIPANSEL (GMI-1070) IN THE TREATMENT OF ONE OR MORE VASOOCCLUSIVE CRISES IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE
-
ASP002 A Phase 2, multicenter, open-label extension study to evaluate the long-term safety and
tolerability of rozanolixizumab in adult study participants with primary antiphospholipid
syndrome.
-
Activation of Sickle Red Cell Adhesion
-
Adapting and Optimizing Gerofit Exercise Intervention for Older Adults with Sickle Cell Disease
-
Adrenergic Receptor Variants and RBC Adhesion in SCD
-
American Society for Apheresis (ASFA) Heparin Induced Thrombocytopenia Registry
-
An Open label extension study of GBT440 administered orally to patients with sickle cell disease who have participated in GBT440 clinical trials
-
An Open-Label, Expanded Access Protocol for Patients with Sickle
Cell Disease Who Have No Alternative Treatment Options - GBT 440-037
-
Anthos ANT-007
-
Anthos ANT-008
-
Anticoagulation Withdrawal in Antiphospholipid Syndrome
-
Apixaban for the Secondary prevention of Thromboembolism: a prospective, randomized, outcome pilot study amount patients with AntiphosPholipid Syndrome (ASTRO-APS)
-
Arginine, Nitric Oxide, and Severe Malaria
-
BIACORE 3000 Biosensor
-
Biological Significance of Protamine/Heparin Antibodies
-
Biological Significance of Protamine/Heparin Antibodies
-
Biological Significance of Protatmine/Heparin Antibodies
-
Burroughs Wellcome Travel Fund-Assessment of endothelial glycocalyz in normal children in a malaria endemic area of Africa
-
COVID-19 Vaccine Response in People Living with Sickle Cell Disease
-
CSA - Pfizer 212511 B5201002 Phase 3 Randomized Multicenter Trial
-
Cellular Basis of HIT Immune Response in Cardiac Surgery
-
Central Carolinas Clinical Trials Collaboration (C3TC)
-
Characterizing frailty in older adults with sickle cell disease using a sickle cell frailty index (FI-SCD)
-
Cilia as a biomarker of CNS vascular health
-
Clinical Significance of protamine/heparin antibodies after CPB
-
Clinical Study Protocol for External Performance Evaluation of INNOVANCE Heparin on BCS XP, Method Comparison
-
Clinical Study Protocol for External Performance Evaluation of INNOVANCE Heparin on BCS XP¿Method Comparison
-
Complement and CR2/CD21 in the Immune Pathogenesis of HIT(R01)
-
Complement and Thrombosis in HIT
-
DU176b-A-U157/ A Phase 1, Open-Label, Single-Dose Non-Randomized Study To Evaluate Pharmacokinetics And Pharmacodynamics of Edoxaban In Pediatric Patients
-
Defining the role of therapeutic plasma exchange in heparin induced thrombocytopenia
-
Developing apheresis-specific outcomes to facilitate a multi-center study of therapeutic plasma exchange in heparin-induced thrombocytopenia
-
Duke-UNC Clinical Hematology and Transfusion Research Career Development Program
-
Duke/UNC Comprehensive Sickle Cell Center
-
Education and Mentoring to Bring Access to Comprehensive Care (EMBRACE) Network
-
Erythropoietin Receptor Regulation of Erythorpoiesis
-
Erythropoietin Receptors in Breast Cancer
-
Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial of MSY-188 injection in children with Sickle Cell disease experiencing vaso-occlusive crisis.
-
Evaluation of an Automated Information Extraction Tool for Identification of Venous Thromboembolism in Electronic Health Records (EHRs)
-
Evaluation, analysis, and dissemination of population-based cancer-associated venous thromboembolism (VTE) data
-
Extension of Hematologic & Clinical Genotype-Phenotype Associations in SCD Using Exome Chip & Metabolomic Analysis
-
External Evaluation of Assay Applications on The Sysmex CS2500 and CS-5100 Analyzer (Wave C)
-
FORMA FT4202-Hem-301 PRAISE PTV. An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE).
-
FORMA Therapeutics FT-4202
-
Factor XIII and Fibrinogen: Mechanisms of Genetic Risk in SCD-Related Priapism
-
Factors Involved in B-CAM/LU-Mediated Adhesion
-
Field Study to evaluate the activity of a site specific of B-Domain Deleted (BDD) pegylated recombinant FVIII protein (BAY 94-9027) in plasma samples measured with both chromogenic and one stage assa
-
Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES)
-
GBT 440-4R1 Retrospective Registry
-
GBT 440-4R2 Prospective Registry
-
GBT-2104-132
-
GBT2104-131 A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease (SCD) Experiencing Vaso-occlusive Crisis (VOCs)
-
GBT2104-133 - An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial
-
GBT440-039 A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults with Sickle Cell Disease
-
GMI Technology vascular occlusion evaluation
-
HITSOVA Danaporiod vs Argatroban Phase III open-label, randomized trial
-
Hematology & Transfusion Medicine (T32)
-
High-throughput Metabolite Profiling and Genetic Analyses to Identify Novel Predictive Biomarkers of SCD-related Complications
-
Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain
-
Hydroxyurea Pharmacokinetics and Pharmacodynamics in Adults with Sickle Cell Anemia
-
IL APS Fresh vs Frozen Clinical Agreement
-
IL ASP Clinical Outcome Study Agreement
-
IPA - James Nishimuta
-
IPA - Robert A. Nielsen
-
IPA - Robert Nielsen
-
IPA - Stephen H. Johnson
-
IPA - Youwei Chen
-
IPA - Youwei Chen
-
IPA - Youwei Chen
-
IPA for Youwei Chen
-
IPA-Youwei Chen
-
Immune Dysregulation in HIT
-
Impact of Daily Prophylaxis Dose Anticoagulation with a Factor Xa Inhibitor (Apixaban) in Patients with Sickle Cell Disease
-
Improving Pain in Sickle Cell Patients With Targeted Antithrombotic Therapy
-
Improving venous thromboembolism surveillance with natural language processing
-
Inducible NOS as a Treatment Target in CLL
-
L000013105 Protocol for Reagent Reproducibility of Liquid Anti-Xa Assay with Apixaban Calibrators on ACL TOP Analyzers
-
L0022511987 Rev 01 Hemosil, Liquid Anti-Xa Assay with Apixaban Calibrators and Controls Performance Evaluation and Fresh vs Frozen Stability Protocol on ACL. TOP 50 Family Series Analyzers
-
L0022511991 Rev 01 Liquid Anti-Xa Assay with Rivaroxaban Calibrators and Controls Performance Evaluation Protocol on ACL TOP
-
LOO22511932 Rev 01 Hemosil Direct Thrombin Inhibitor (DTI) Assay with Dabigatran Calibrators and Controls
-
Lateral Flow Hemoglobinopathies Test Development
-
MOMENTA MOM-M281-006
-
MST-188-04 EVALUATION OF REPEAT ADMINISTRATION OF PURIFIED POLOXAMER 188 IN VASO-OCCLUSIVE CRISIS OF SICKLE CELL DISEASE (EPIC-E): AN OPEN-LABEL SAFETY EXTENSION TRIAL ASSESSING REPEAT ADMINISTRATION OF MST-188 (PURIFIED POLOXAMER 188) INJECTION IN
-
Minority Invest Post-Bacc Res. Supp. - T Jackson
-
Modeling the spectrum of HIT pathobiology
-
Molecular Biology Of Human Coagulation Factor V
-
Multi-site Clinical Laboratory Testing for SickleScan
-
Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age- and body-weight-adjusted rivaroxaban regimen in children with acute venous thromboembolism
-
NC DHHS Sickle Cell Contract
-
Neutrophil Activation Phenotypes in Healthy Subjects and Implications for Bacterial Clearance
-
Neutrophil activation responses to platelet factor 4/heparin immune complexes
-
Nitric Oxide and Malaria
-
Nitric Oxide and Microvascular Dysfunction in Severe Malaria
-
Obizur EU PASS. Prospective and retrospective, non-interventional study to evaluate the safety and effectiveness of Obizur in real-life practice.
-
Open Label study to evaluate the safety and Pharmacokinetics of PF-06412528 in children 7-17 for treatment of moderate to severe pain
-
Outcome Modifying Genes in Sickle Cell Diseases
-
Oxidative stress mechanisms regulating gamma-globin gene transcription in sickle cell disease
-
PBI - Determination of Reproducibility and Accuracy of CRYOcheck Factor VIII Deficient Plasma with VWF
-
PC-ChFVIIa Proof of Concept Studies
-
PFIZER B0401016
-
POST-MARKETING non-interventional safety evaluation of obizur in the treatment of bleeding episodes for patients with acquired hemophilia A
-
PRIDE-Functional and Translational Genomics of Blood Disorders
-
PROPRANOLOL AS ANTI-ADHESIVE THERAPY IN SCD
-
Pathogenesis of Thrombosis in HIT
-
Phase 3, prospective, randomized, controlled study of prophylatic and on-demand treatment of cTTP with BAX930 (rADAMTS13)
-
Phase II Study of Propranolol as Anti-Adhesive Therapy in SCD
-
Phase II study of SEG101 in sickle cell disease patients with Prisprism (SPARTAN)
-
Phase II study to assess SEG101 in Sickle Cell Patients
-
Phase II, of oral SKI-O-703 in Chronic Immune Thrombocytopenia (ITP)
-
Phase III study of AG-348 in not regulary transfused adult subjects with Pyruvate kinase deficiency
-
Population-based Surveillance And Ourcomes of Venous Thromboembolism
-
Population-based Surveillance And Outcomes of Venous Thromboembolism
-
Precision Performance of STA® -COAG CONTROL (N + ABN) PLUS ON STA -SATELLITE®
-
Probing the heparin structural elements for high risk of heparin-induced thrombocytopenia (HIT)
-
Probing the heparin structural elements for high risk of heparin-induced thrombocytopenia (HIT)
-
Promoting the Health of Individuals with Clotting Disorders
-
Public Health Surveillance of Bleeding
-
Pulmonary Hypertension in SCD
-
QuBBD: Collaborative Research: Advancing mHealth using Big Data Analytics: Statistical and Dynamical Systems Modeling of Real-Time Adaptive m-Intervention for Pain
-
Randomized double-blind study of FT-4202 in sickle cell disease
-
Rapid point of care diagnostics to detect serologic status of individuals for select viral infections
-
Rare Thrombotic Diseases Clinical Research Network
-
Relationship of Depression to SCD Severity, Health Care Utilization and QoL
-
Role of Complement Receptors in cellualr activation by HIT immune complexes
-
Role of Erythropoietin Receptor Signaling in the Heart
-
Role of RBC NO and ATP in Sickle Vasculopathy
-
Role of RBC Reactive Oxygen Species and Their Vicious Cycle in Sickle Vasculopathy
-
Role of myeloid KLF2 in antiphospholipid antibody-mediated thrombosis
-
SCH: INT: Collaborative Research: Development and analysis of integrative models for chronic pain
-
STA - Coag Control ABN PLUS Precision Study
-
SUCCESSOR Chart Review
-
SUSTAIN (A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SEIGI With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises
-
Same
-
Sharing Comprehensive 'Omics in Sickle Cell Disease Through the NHLBI TOPMed Network
-
Shire SC Study (A Phase 1/2 randomized, double-blind, placebo-controlled,
multicenter, ascending dose, safety and PK/PD study of SHP655
(rADAMTS13) in sickle cell disease at baseline health and
during acute vaso-occlusive crisis.)
-
Sickle Cell Disease Structured Transition Education Intervention With Peer Mentoring Support to Improving Care Transitions (SCD ST3P-UP Program)
-
Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
-
Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
-
Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE)
-
Sickle Cell Treatment Demonstration
-
Siemans/VWF - Hemosil and REAADS Study
-
Siemens CS-2100i and CS-5100 New Generation Analyzers
-
Stago - STA-NeoPTimal 5ml and 10 ml Single Site Precision Study
-
Stago - STA-NeoPTimal 5ml and 10m: Multisite Precision Study
-
Stago NeoPTimal 5 mL and 10 mL Multi-Site Precision Study
-
Stago STA® - NeoPTimal 5 and 10 mL Single Site Precision Study
-
Stago themO® CE marking according to IVDR of DDi M reagent
-
Task Order 1 under Master Eval Agreement #17072705
-
Testing The Effect Of Ferroportin Inhibitor On Sickle Cell Pathophysiology
-
ThRombosis exelUsion STudy for STA - Liatest D-DiXL (TRUST)
-
Thalassemia Screening in Myanmese and Lao Migrants in Thailand
-
The Role of RBC Reactive Oxygen Species in Regulating Thrombotic Events During Aging
-
The Role of Surface Immunoglobulin Isotype in Chronic Lymphocytic Leukemia Disease Biology and Clinical Outcomes in the Era of the Novel Agents
-
Thrombosis and Hemostasis Centers Research and Prevention Network
-
Tissue Transglutaminase in Neurologic Injury
-
Transfusion Medicine/Hemostasis Core Clinical Center
-
U.S. External Site Protocol for Evaluation of Precision Performances of STA-THROMBIN ON STA-SATELLITE
-
Understanding and Enhancing the Therapeutic Efficacy of Factor VIIa for Emergency Hemostasis
-
Use of Mobile Technology for Intensive Training in Medication Management
-
Use of Mobile Technology to Improve Acute Care Utilization in Sickle Cell Disease
-
Variability in neutrophil activation
-
aHUS Study LNP023/Novartis. A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy.
-
same